Targeting the Wnt/β-catenin signaling pathway in human cancers

Bibliography

• Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006;127:469-80
   PubMed Web of Science ®Google Scholar
• Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006;5:997-1014
   PubMed Web of Science ®Google Scholar
• Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004;15:691-701
   Google Scholar
• Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis 2008;4:68-75
   PubMedGoogle Scholar
• Kinzler KW, Nilbert MC, Su LK, Identification of FAP locus genes from chromosome 5q21. Science 1991;253:661-5
   PubMed Web of Science ®Google Scholar
• Nishisho I, Nakamura Y, Miyoshi Y, Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991;253:665-9
   PubMed Web of Science ®Google Scholar
• Mikami I, You L, He B, Efficacy of Wnt-1 monoclonal antibody in sarcoma cells. BMC Cancer 2005;5:53
   PubMed Web of Science ®Google Scholar
• Wei W, Chua MS, Grepper S, So SK. Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Mol Cancer 2009;8:76
   PubMed Web of Science ®Google Scholar
• He B, You L, Uematsu K, A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 2004;6:7-14
   PubMed Web of Science ®Google Scholar
• Ashihara E, Kawata E, Nakagawa Y, beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model. Clin Cancer Res 2009;15:2731-8
   PubMed Web of Science ®Google Scholar
• Verma UN, Surabhi RM, Schmaltieg A, Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003;9:1291-300
   PubMed Web of Science ®Google Scholar
• Boon EM, Keller JJ, Wormhoudt TA, Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer 2004;90:224-9
   PubMed Web of Science ®Google Scholar
• Dihlmann S, Klein S, von Knebel Doeberitz M. Reduction of beta-catenin/T-cell transcription factor signaling by aspirin and indomethacin is caused by an increased stabilization of phosphorylated beta-catenin. Mol Cancer Ther 2003;2:509-16
   PubMed Web of Science ®Google Scholar
• Hawcroft G, D'Amico M, Albanese C, Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells. Carcinogenesis 2002;23:107-14
   PubMed Web of Science ®Google Scholar
• Rao AS, Kremenevskaja N, von Wasielewski R, Wnt/beta-catenin signaling mediates antineoplastic effects of imatinib mesylate (gleevec) in anaplastic thyroid cancer. J Clin Endocrinol Metab 2006;91:159-68
   PubMed Web of Science ®Google Scholar
• Zhou L, An N, Haydon RC, Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity. Cancer Lett 2003;193:161-70
   PubMed Web of Science ®Google Scholar
• Miller JR. The Wnts. Genome Biol 2002;3(1):reviews3001-3001.15
   PubMedGoogle Scholar
• Hsieh JC, Kodjabachian L, Rebbert ML, A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 1999;398:431-6
   PubMed Web of Science ®Google Scholar
• Jones SE, Jomary C. Secreted Frizzled-related proteins: searching for relationships and patterns. Bioessays 2002;24:811-20
   PubMed Web of Science ®Google Scholar
• Mao B, Wu W, Li Y, LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001;411:321-5
   PubMed Web of Science ®Google Scholar
• Liu C, Li Y, Semenov M, Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002;108:837-47
   PubMed Web of Science ®Google Scholar
• Amit S, Hatzubai A, Birman Y, Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev 2002;16:1066-76
   PubMed Web of Science ®Google Scholar
• Latres E, Chiaur DS, Pagano M. The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene 1999;18:849-54
   PubMed Web of Science ®Google Scholar
• Kitagawa M, Hatakeyama S, Shirane M, An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin. Embo J 1999;18:2401-10
   PubMed Web of Science ®Google Scholar
• Cavallo RA, Cox RT, Moline MM, Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Nature 1998;395:604-8
   PubMed Web of Science ®Google Scholar
• Roose J, Molenaar M, Peterson J, The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. Nature 1998;395:608-12
   PubMed Web of Science ®Google Scholar
• Donnellan R, Chetty R. Cyclin D1 and human neoplasia. Mol Pathol 1998;51:1-7
   PubMedGoogle Scholar
• Zhang T, Otevrel T, Gao Z, Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 2001;61:8664-7
   PubMed Web of Science ®Google Scholar
• Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol 2001;2:667-73
   PubMed Web of Science ®Google Scholar
• Zhang X, Gaspard JP, Chung DC. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 2001;61:6050-4
   PubMed Web of Science ®Google Scholar
• Hecht A, Vleminckx K, Stemmler MP, The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. Embo J 2000;19:1839-50
   PubMed Web of Science ®Google Scholar
• Kramps T, Peter O, Brunner E, Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell 2002;109:47-60
   PubMed Web of Science ®Google Scholar
• Stadeli R, Basler K. Dissecting nuclear Wingless signalling: recruitment of the transcriptional co-activator Pygopus by a chain of adaptor proteins. Mech Dev 2005;122:1171-82
   PubMed Web of Science ®Google Scholar
• Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 2003;129:199-221
   PubMed Web of Science ®Google Scholar
• Herbst A, Kolligs FT. Wnt signaling as a therapeutic target for cancer. Methods Mol Biol 2007;361:63-91
   PubMedGoogle Scholar
• Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84
   PubMed Web of Science ®Google Scholar
• Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 2005;45:872-7
   PubMed Web of Science ®Google Scholar
• De Sousa EMF, Vermeulen L, Richel DJ, Medema JP. Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res 2011;17:647-53
   PubMed Web of Science ®Google Scholar
• Vermeulen L, De Sousa EMF, van der Heijden M, Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010;12:468-76
   PubMed Web of Science ®Google Scholar
• Malanchi I, Peinado H, Kassen D, Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 2008;452:650-3
   PubMed Web of Science ®Google Scholar
• Li Y, Welm B, Podsypanina K, Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci USA 2003;100:15853-8
   PubMed Web of Science ®Google Scholar
• Jamieson CH, Ailles LE, Dylla SJ, Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657-67
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009;28:15-33
   PubMed Web of Science ®Google Scholar
• Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 2010;15:117-34
   PubMed Web of Science ®Google Scholar
• Onder TT, Gupta PB, Mani SA, Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008;68:3645-54
   PubMed Web of Science ®Google Scholar
• Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009;28:151-66
   PubMed Web of Science ®Google Scholar
• Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6
   PubMed Web of Science ®Google Scholar
• Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21
   PubMed Web of Science ®Google Scholar
• Giardiello FM, Hamilton SR, Krush AJ, Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-16
   PubMed Web of Science ®Google Scholar
• Eberhart CE, Coffey RJ, Radhika A, Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8
   PubMed Web of Science ®Google Scholar
• Castellone MD, Teramoto H, Williams BO, Prostaglandin E2 promotes colon cancer cell growth through a GS-axin-beta-catenin signaling axis. Science 2005;310:1504-10
   PubMed Web of Science ®Google Scholar
• Li H, Liu L, David ML, Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation. Biochem Pharmacol 2002;64:1325-36
   PubMed Web of Science ®Google Scholar
• Rice PL, Kelloff J, Sullivan H, Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. Mol Cancer Ther 2003;2:885-92
   PubMed Web of Science ®Google Scholar
• Tuynman JB, Vermeulen L, Boon EM, Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res 2008;68:1213-20
   PubMed Web of Science ®Google Scholar
• Sato H, Suzuki H, Toyota M, Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors. Carcinogenesis 2007;28:2459-66
   PubMed Web of Science ®Google Scholar
• Tsuji T, Nozaki I, Miyazaki M, Antiproliferative activity of REIC/Dkk-3 and its significant down-regulation in non-small-cell lung carcinomas. Biochem Biophys Res Commun 2001;289:257-63
   PubMed Web of Science ®Google Scholar
• Suzuki H, Watkins DN, Jair KW, Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004;36:417-22
   PubMed Web of Science ®Google Scholar
• He B, Reguart N, You L, Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 2005;24:3054-8
   PubMed Web of Science ®Google Scholar
• Schlange T, Matsuda Y, Lienhard S, Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res 2007;9:R63
   PubMed Web of Science ®Google Scholar
• Akiri G, Cherian MM, Vijayakumar S, Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene 2009;28:2163-72
   PubMed Web of Science ®Google Scholar
• Katoh M. Expression and regulation of WNT1 in human cancer: up-regulation of WNT1 by beta-estradiol in MCF-7 cells. Int J Oncol 2003;22:209-12
   PubMed Web of Science ®Google Scholar
• Ashihara E, Kawata E, Maekawa T. Future prospect of RNA interference for cancer therapies. Curr Drug Targets 2010;11:345-60
   PubMed Web of Science ®Google Scholar
• Chim CS, Pang R, Fung TK, Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia 2007;21:2527-36
   PubMed Web of Science ®Google Scholar
• Peer D, Park EJ, Morishita Y, Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008;319:627-30
   PubMed Web of Science ®Google Scholar
• Brembeck FH, Rosario M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev 2006;16:51-9
   PubMed Web of Science ®Google Scholar
• Miravet S, Piedra J, Castano J, Tyrosine phosphorylation of plakoglobin causes contrary effects on its association with desmosomes and adherens junction components and modulates beta-catenin-mediated transcription. Mol Cell Biol 2003;23:7391-402
   PubMed Web of Science ®Google Scholar
• Roura S, Miravet S, Piedra J, Regulation of E-cadherin/catenin association by tyrosine phosphorylation. J Biol Chem 1999;274:36734-40
   PubMed Web of Science ®Google Scholar
• Piedra J, Miravet S, Castano J, p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin–alpha-catenin interaction. Mol Cell Biol 2003;23:2287-97
   PubMed Web of Science ®Google Scholar
• Kimura S, Ashihara E, Maekawa T. New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Curr Pharm Biotechnol 2006;7:371-9
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Cortes J. Imatinib and beyond-exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 2009;6:535-43
   PubMed Web of Science ®Google Scholar
• Lepourcelet M, Chen YN, France DS, Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 2004;5:91-102
   PubMed Web of Science ®Google Scholar
• von Kries JP, Winbeck G, Asbrand C, Hot spots in beta-catenin for interactions with LEF-1, conductin and APC. Nat Struct Biol 2000;7:800-7
   PubMedGoogle Scholar
• Omer CA, Miller PJ, Diehl RE, Kral AM. Identification of Tcf4 residues involved in high-affinity beta-catenin binding. Biochem Biophys Res Commun 1999;256:584-90
   PubMed Web of Science ®Google Scholar
• Sukhdeo K, Mani M, Zhang Y, Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 2007;104:7516-21
   PubMed Web of Science ®Google Scholar
• Wei W, Chua MS, Grepper S, So S. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo. Int J Cancer 2010;126:2426-36
   PubMed Web of Science ®Google Scholar
• Gandhirajan R, Gehrke I, Filipovich A, Potent antineoplastic activity of two inhibitors of lymphoid enhancer binding factor-1 (LEF-1) in Chronic Lymphocytic Leukemia (B-CLL) [abstract 885]. American Society of Hematology (ASH) meeting; 2009; New Orleans; 2009. Available from: http://ash.confex.com/ash/2009/webprogram/Paper21676.html [Last accessed 1 April 2011]
   Google Scholar
• Coghlan MP, Culbert AA, Cross DA, Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 2000;7:793-803
   PubMed Web of Science ®Google Scholar
• Emami KH, Nguyen C, Ma H, A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci USA 2004;101:12682-7
   PubMed Web of Science ®Google Scholar
• Huang SM, Mishina YM, Liu S, Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009;461:614-20
   PubMed Web of Science ®Google Scholar
• Chen B, Dodge ME, Tang W, Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009;5:100-7
   PubMed Web of Science ®Google Scholar
• Park S, Gwak J, Cho M, Hexachlorophene inhibits Wnt/beta-catenin pathway by promoting Siah-mediated beta-catenin degradation. Mol Pharmacol 2006;70:960-6
   PubMed Web of Science ®Google Scholar
• Gwak J, Song T, Song JY, Isoreserpine promotes beta-catenin degradation via Siah-1 up-regulation in HCT116 colon cancer cells. Biochem Biophys Res Commun 2009;387:444-9
   PubMed Web of Science ®Google Scholar
• Bol D, Ebner R. Gene expression profiling in the discovery, optimization and development of novel drugs: one universal screening platform. Pharmacogenomics 2006;7:227-35
   PubMed Web of Science ®Google Scholar
• Yao H, Ashihara E, Nagao R, AV-65, a Novel inhibitor of the Wnt/beta-catenin signaling pathway, inhibits the proliferation of myeloma cells [abstract 2866]. American Society of Hematology (ASH) meeting; 2009; New Orleans; 2009. Available from: http://ash.confex.com/ash/2009/webprogram/Paper17043.html. [Last accessed 1 April 2011]
   Google Scholar
• Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-50
   PubMed Web of Science ®Google Scholar
• Chen X, Yang J, Evans PM, Liu C. Wnt signaling: the good and the bad. Acta Biochim Biophys Sin (Shanghai) 2008;40:577-94
   PubMed Web of Science ®Google Scholar
• Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006;355:1253-61
   PubMed Web of Science ®Google Scholar
• Reya T, Duncan AW, Ailles L, A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003;423:409-14
   PubMed Web of Science ®Google Scholar
• Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest 2006;116:1202-9
   PubMed Web of Science ®Google Scholar
• Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene 2004;341:19-39
   PubMed Web of Science ®Google Scholar
• Situ DR, Hu Y, Zhu ZH, Prognostic relevance of beta-catenin expression in T2-3N0M0 esophageal squamous cell carcinoma. World J Gastroenterol 2010;16:5195-202
   PubMed Web of Science ®Google Scholar
• Elzagheid A, Buhmeida A, Korkeila E, Nuclear beta-catenin expression as a prognostic factor in advanced colorectal carcinoma. World J Gastroenterol 2008;14:3866-71
   PubMed Web of Science ®Google Scholar
• Martensson A, Oberg A, Jung A, beta-catenin expression in relation to genetic instability and prognosis in colorectal cancer. Oncol Rep 2007;17:447-52
   PubMed Web of Science ®Google Scholar
• Holcombe RF, Marsh JL, Waterman ML, Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. Mol Pathol 2002;55:220-6
   PubMedGoogle Scholar
• Park JK, Song JH, He TC, Overexpression of Wnt-2 in colorectal cancers. Neoplasma 2009;56:119-23
   PubMed Web of Science ®Google Scholar
• Rhee CS, Sen M, Lu D, Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas. Oncogene 2002;21:6598-605
   PubMed Web of Science ®Google Scholar
• Katoh M, Kirikoshi H, Terasaki H, Shiokawa K. WNT2B2 mRNA, up-regulated in primary gastric cancer, is a positive regulator of the WNT-beta-catenin-TCF signaling pathway. Biochem Biophys Res Commun 2001;289:109310-98
   Web of Science ®Google Scholar
• Pham K, Milovanovic T, Barr RJ, Wnt ligand expression in malignant melanoma: pilot study indicating correlation with histopathological features. Mol Pathol 2003;56:280-5
   PubMedGoogle Scholar
• Hall CL, Bafico A, Dai J, Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005;65:7554-60
   PubMed Web of Science ®Google Scholar
• Terasaki H, Saitoh T, Shiokawa K, Katoh M. Frizzled-10, up-regulated in primary colorectal cancer, is a positive regulator of the WNT – beta-catenin – TCF signaling pathway. Int J Mol Med 2002;9:107-12
   PubMed Web of Science ®Google Scholar
• To KF, Chan MW, Leung WK, Alterations of frizzled (FzE3) and secreted frizzled related protein (hsFRP) expression in gastric cancer. Life Sci 2001;70:483-9
   PubMed Web of Science ®Google Scholar
• Nagayama S, Fukukawa C, Katagiri T, Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas. Oncogene 2005;24:6201-12
   PubMed Web of Science ®Google Scholar
• Qi J, Zhu YQ, Luo J, Tao WH. Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor. World J Gastroenterol 2006;12:7113-17
   PubMed Web of Science ®Google Scholar
• Caldwell GM, Jones C, Gensberg K, The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res 2004;64:883-8
   PubMed Web of Science ®Google Scholar
• Suzuki H, Toyota M, Carraway H, Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer 2008;98:1147-56
   PubMed Web of Science ®Google Scholar
• Klopocki E, Kristiansen G, Wild PJ, Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol 2004;25:641-9
   PubMed Web of Science ®Google Scholar
• Cheng YY, Yu J, Wong YP, Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. Br J Cancer 2007;97:895-901
   PubMed Web of Science ®Google Scholar
• Nojima M, Suzuki H, Toyota M, Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene 2007;26:4699-713
   PubMed Web of Science ®Google Scholar
• Zhang YW, Miao YF, Yi J, Transcriptional inactivation of secreted frizzled-related protein 1 by promoter hypermethylation as a potential biomarker for non-small cell lung cancer. Neoplasma 2010;57:228-33
   PubMed Web of Science ®Google Scholar
• Fukui T, Kondo M, Ito G, Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in non-small-cell lung cancer. Oncogene 2005;24:6323-7
   PubMed Web of Science ®Google Scholar
• Liu TH, Raval A, Chen SS, CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res 2006;66:653-8
   PubMed Web of Science ®Google Scholar
• Marsit CJ, Karagas MR, Andrew A, Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res 2005;65:7081-5
   PubMed Web of Science ®Google Scholar
• Aguilera O, Fraga MF, Ballestar E, Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 2006;25:4116-21
   PubMed Web of Science ®Google Scholar
• Yu J, Tao Q, Cheng YY, Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Cancer 2009;115:49-60
   PubMed Web of Science ®Google Scholar
• Ai L, Tao Q, Zhong S, Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis 2006;27:1341-8
   PubMed Web of Science ®Google Scholar
• Wissmann C, Wild PJ, Kaiser S, WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 2003;201:204-12
   PubMed Web of Science ®Google Scholar
• Mazieres J, He B, You L, Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 2004;64:4717-20
   PubMed Web of Science ®Google Scholar
• Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70
   PubMed Web of Science ®Google Scholar
• Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000;103:311-20
   PubMed Web of Science ®Google Scholar
• Miyaki M, Konishi M, Kikuchi-Yanoshita R, Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. Cancer Res 1994;54(11):3011-20
   PubMed Web of Science ®Google Scholar
• Clement G, Braunschweig R, Pasquier N, Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus. Oncogene 2006;25:3084-92
   PubMed Web of Science ®Google Scholar
• Kitaeva MN, Grogan L, Williams JP, Mutations in beta-catenin are uncommon in colorectal cancer occurring in occasional replication error-positive tumors. Cancer Res 1997;57:4478-81
   PubMed Web of Science ®Google Scholar
• Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998;58:1130-4
   PubMed Web of Science ®Google Scholar
• Woo DK, Kim HS, Lee HS, Altered expression and mutation of beta-catenin gene in gastric carcinomas and cell lines. Int J Cancer 2001;95:108-13
   PubMed Web of Science ®Google Scholar
• Park WS, Oh RR, Park JY, Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res 1999;59:4257-60
   PubMed Web of Science ®Google Scholar
• Miyoshi Y, Iwao K, Nagasawa Y, Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 1998;58:2524-7
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Roberts LR, Aderca IN, Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002;21:4863-71
   PubMed Web of Science ®Google Scholar
• Palacios J, Gamallo C. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 1998;58:1344-7
   PubMed Web of Science ®Google Scholar
• Koesters R, Ridder R, Kopp-Schneider A, Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res 1999;59:3880-2
   PubMed Web of Science ®Google Scholar
• Liu W, Dong X, Mai M, Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet 2000;26:146-7
   PubMed Web of Science ®Google Scholar